{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T17:26:26Z","timestamp":1720545986566},"reference-count":17,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":700,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research (NIHR)","doi-asserted-by":"crossref","award":["RP-PG-0407-10177"],"award-info":[{"award-number":["RP-PG-0407-10177"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"L'Or\u00e9al Research & Innovation and Beiersdorf"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1111\/bjd.12530","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T04:58:17Z","timestamp":1444712297000},"page":"67-70","source":"Crossref","is-referenced-by-count":3,"special_numbering":"supplement s3","title":["Future horizons in vitiligo research: focusing on the recommendations of the Cochrane systematic review \u2018Interventions for vitiligo\u2019 2010"],"prefix":"10.1093","volume":"169","author":[{"given":"V.","family":"Eleftheriadou","sequence":"first","affiliation":[{"name":"Centre of Evidence Based Dermatology; University of Nottingham; Nottingham U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,10,4]]},"reference":[{"key":"10.1111\/bjd.12530-BIB0001|bjd12530-cit-0001","first-page":"ED000037","article-title":"Implications for research: getting the most out of Cochrane reviews","volume":"1","author":"Gonzalez","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.12530-BIB0002|bjd12530-cit-0002","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"10.1111\/bjd.12530-BIB0003|bjd12530-cit-0003","first-page":"CD003263","article-title":"Interventions for vitiligo","volume":"1","author":"Whitton","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.12530-BIB0004|bjd12530-cit-0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0378-6323.32708","article-title":"Vitiligo: compendium of clinico-epidemiological features","volume":"73","author":"Sehgal","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1111\/bjd.12530-BIB0005|bjd12530-cit-0005","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1111\/bjd.12530-BIB0006|bjd12530-cit-0006","first-page":"530","article-title":"Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership","volume":"164","author":"Eleftheriadou","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12530-BIB0007|bjd12530-cit-0007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","article-title":"The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force","volume":"20","author":"Taieb","year":"2007","journal-title":"Pigment Cell Res"},{"key":"10.1111\/bjd.12530-BIB0008|bjd12530-cit-0008","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archderm.140.6.677","article-title":"Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index","volume":"140","author":"Hamzavi","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12530-BIB0009|bjd12530-cit-0009","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","article-title":"Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials","volume":"167","author":"Eleftheriadou","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12530-BIB0010|bjd12530-cit-0010","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1046\/j.1523-1747.2003.12251.x","article-title":"Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring?","volume":"120","author":"Charman","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.12530-BIB0011|bjd12530-cit-0011","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4155\/cli.13.21","article-title":"Core outcomes in vitiligo trials: progress and challenges [Editorial]","volume":"3","author":"Eleftheriadou","year":"2013","journal-title":"Clin Invest"},{"key":"10.1111\/bjd.12530-BIB0012|bjd12530-cit-0012","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/archdermatol.2011.235","article-title":"Guidelines for designing and reporting clinical trials in vitiligo","volume":"147","author":"Gonzalez","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12530-BIB0013|bjd12530-cit-0013","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/bmj.328.7438.475","article-title":"Well informed uncertainties about the effects of treatments","volume":"328","author":"Chalmers","year":"2004","journal-title":"BMJ"},{"key":"10.1111\/bjd.12530-BIB0014|bjd12530-cit-0014","first-page":"56","volume-title":"The James Lind Alliance (JLA) Guidebook","author":"James Lind Alliance","year":"2010"},{"key":"10.1111\/bjd.12530-BIB0015|bjd12530-cit-0015","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/AOG.0b013e3181c3020d","article-title":"Avoidable waste in the production and reporting of research evidence","volume":"114","author":"Chalmers","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1111\/bjd.12530-BIB0016|bjd12530-cit-0016","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2133.2008.08881.x","article-title":"Guideline for the diagnosis and management of vitiligo","volume":"159","author":"Gawkrodger","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12530-BIB0017|bjd12530-cit-0017","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the EDF consensus. By the writing group of the Vitiligo European Task Force (VETF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Europ\u00e9enne des M\u00e9decins Sp\u00e9cialistes (UEMS)","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12530","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12530\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:06:19Z","timestamp":1676383579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/169\/s3\/67\/6614723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1111\/bjd.12530","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}